Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study on Camrelizumab（SHR-1210）for Recurrent Primary Central Nervous System Lymphoma (PCNSL)

NCT04070040 is registered in ClinicalTrials.gov with Beijing Sanbo Brain Hospital as lead sponsor.

NCT NCT04070040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04070040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study on Camrelizumab（SHR-1210）for Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Lead sponsor
Beijing Sanbo Brain Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
February 13, 2020
Completion date
December 31, 2024
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary central nervous system lymphoma